[1] Bruni L, Albero G, Serrano B, et al.ICO/IARC information centre on HPV and cancer (HPV information centre).Human papillomavirus and related diseases report[R]. Summary Report 22 October 2021.https://hpvcentre.net/datastatistics.php [2] Bruni L, Saura-LázaroA, Montoliu A,et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010—2019[J]. Prev Med (Baltim),2021, 144:106399. doi: 10.1016/j.ypmed.2020.106399. [3] 宋祎凡,尹遵栋,余文周,等. 2018-2020 年中国 9-45 岁女性人乳头瘤病毒疫苗估算接种率[J]. 中国疫苗和免疫, 2021, 27: 570-575. [4] Kim HJ, Cho SY, Park MH, et al. Comparison of the size distributions and immunogenicity of human papillomavirus type 16 L1 virus-like particles produced in insect and yeast cells[J]. Arch Pharm Res,2018, 41: 544-553. [5] Mariz FC, Gray P, Bender N,et al. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials[J]. Lancet Infect Dis,2021, 21: 1458-1468. [6] Mariz FC, Bender N, Anantharaman D, et al. Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines[J]. npj Vaccines,2020,5:16-21. [7] Einstein MH, Baron M, Levin MJ,et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: Follow-up from Months 12-24 in a Phase Ⅲ randomized study of healthy women aged 18-45 years[J]. Hum Vaccin,2011, 7:1343-1358. [8] Wang Z, Zhang T, Xu X. Combined truncations at both N- and C-terminus of human papillomavirus type 58 L1 enhanced the yield of virus-like particles produced in a baculovirus system[J]. J Virol Methods,2021,301:114403.doi: 10.1016/j.jviromet.2021.114403. [9] Park MA, Kim HJ,Kim HJ,et al. Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae[J]. Protein Expr Purif,2008,59:175-181. [10] Zhang J, Cheng K, Wang Z. Prevalence and distribution of human papillomavirus genotypes in cervical intraepi-thelial neoplasia in China: a meta-analysis[J]. Arch Gynecol Obstet,2020, 302:1329-1337. [11] Kim HJ, Lim SJ, Kwag HL,et al. The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles[J]. PLoS One,2012, 7:e35893. doi:10.1371/journal.pone.0035893. [12] Baek JO, Seo JW, Kwon O, et al. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophy-lactic vaccine against cervical cancer[J]. Enzyme Microb Technol,2012, 50: 173-180. [13] J.C.库克三世. 纯化人乳头瘤病毒样颗粒的方法:中国, 99811968.7[P]. 2002-06-19. |